Van Doorn R, Kirtschig G, Scheffer E, Stoof T J, Giaccone G
Department of Dermatology, Vrije Universiteit Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands.
Br J Dermatol. 2002 Sep;147(3):598-601. doi: 10.1046/j.1365-2133.2002.04864.x.
We report the cutaneous side-effects of ZD1839 (Iressa), a new anticancer agent that acts by inhibiting epidermal growth factor (EGF) receptor signal transduction. Three patients receiving ZD1839 developed an eruption consisting of follicular papules and pustules in an acneiform distribution as well as diffuse fine scaling of the skin. Additionally, hair growth abnormalities were noted in two patients. Histologically, a superficial purulent folliculitis and disordered differentiation with focal parakeratosis were seen. The follicular eruption appeared to respond favourably to treatment with tretinoin cream and minocycline. The cutaneous adverse effects of ZD1839 are similar to those of other EGF receptor-targeted agents and result from direct interference with the functions of EGF receptor signalling in the skin.
我们报告了ZD1839（易瑞沙）的皮肤副作用，ZD1839是一种新型抗癌药物，通过抑制表皮生长因子（EGF）受体信号转导发挥作用。三名接受ZD1839治疗的患者出现了皮疹，表现为痤疮样分布的毛囊丘疹和脓疱，以及皮肤弥漫性细鳞屑。此外，两名患者出现了毛发生长异常。组织学上，可见浅表脓性毛囊炎和伴有局灶性角化不全的分化紊乱。毛囊性皮疹似乎对角维甲酸乳膏和米诺环素治疗反应良好。ZD1839的皮肤不良反应与其他靶向EGF受体的药物相似，是由于直接干扰皮肤中EGF受体信号传导的功能所致。
